Press release BoxID: 316621 (Sartorius AG)
  • Sartorius AG
  • Weender Landstraße 94-108
  • 37075 Göttingen
  • Contact person
  • Petra Kirchhoff
  • +49 (551) 308-1686

Maik W. Jornitz elected Chair of the Board of the global Parental Drug Association

(PresseBox) (Goettingen (D) / Bethesda (Maryland, USA), ) Maik W. Jornitz, Group Vice President of Global Marketing & Product Management for Filtration | Fermentation Technologies at Sartorius Stedim Biotech, is now Chair of the Board of the Parental Drug Association (PDA). The PDA, headquartered in Bethesda, Maryland, USA, is the leading global notforprofit organization providing science, technology and regulatory information and education for the pharmaceutical and biopharmaceutical community.

Maik Jornitz has been an active member of the PDA since 1994, holding a number of voluntary functions. For instance, he was a member of the task forces that drafted technical reports on sterile filtration and depth filtration and headed the 2008 PDA Annual Meeting. He was elected in 2004 to the Board of Directors and has been Chair-Elect of the Board since 2007. In addition to Jornitz, the PDA Board consisting of 17 members includes representatives from the pharmaceutical companies Pfizer, Novartis, GlaxoSmithKline, Amgen, Baxter, Roche/Genentech, Abbott and Hoffmann-La-Roche. Maik Jornitz's term as PDA Chair will run until the end of 2011.

Maik W. Jornitz has been with the Sartorius Group for 23 years. The biotech manager is an internationally recognized expert in filtration technologies with a focus on sterile filtration, process validation and integrity testing for biopharmaceutical applications. He has already authored and coauthored nine scientific books and seven chapters, and regularly publishes technical papers in scientific and trade journals.

The notforprofit PDA organization has over 10,000 members worldwide, who predominantly work at companies, research institutes and government agencies that deal with the development, manufacture, quality control and approval of drugs and other pharmaceutical products.

Sartorius AG

Sartorius Stedim Biotech is a leading provider of cuttingedge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. For next generation processes, Sartorius Stedim Biotech focuses on singleuse technologies and valueadded services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions" on a daily basis.

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs over 2,300 people, and in 2008 generated sales revenue of 368.0 million euros.